Galapagos, акция обыкновенная (BE0003818359, GLPG, 0JXZ, GXE)

Lakefront Biotherapeutics NV is a Belgiumbased company. The Company develops medicines for patients with serious diseases in areas of unmet medical need and uses dealmaking capabilities and capital to identify, acquire, and advance opportunities that create value for patients and shareholders. Its pipeline includes clinicalstage immunology and oncology programs, such as autoimmune disease candidates and selected oncology assets, primarily advanced through partnerships and targeted development rather than inhouse cell therapy platforms. It builds a portfolio of clinicalstage therapies intended to support existing treatment approaches and operates across oncology and immunology and inflammation programs supported by clinical proof of concept in emerging therapeutic areas.

• Galapagos, Бразильская депозитарная расписка (БДР), BRG1LPBDR002
• Lakefront Biotherapeutics, Американская депозитарная расписка (АДР), US36315X1019
• Lakefront Biotherapeutics, Бразильская депозитарная расписка (БДР), BRB100ACNOR0

• Выручка
• Чистая прибыль
• EBITDA
• Активы
• Капитал
• Рентабельность по EBITDA (%)
• Чистый долг / EBITDA
• Общий долг / Капитал